J Clin Exp Pathol 2015 Mar http / /www. cnki. net /kcms /detail / R html. anaplastie lymphoma kinase ALK ALK

Transcript

1 http / /www. cnki. net /kcms /detail / R html ALK immunohistochemistry IHC ALK anaplastie lymphoma kinase ALK non-small cell lung cancer NSCLC ALK 60 NSCLC 4 D5F3 Ventana D5F3 Cell Signaling 1A4 /1H7 OriGene 5A4 Abcam IHC NSCLC ALK D5F3 Ventana IHC BenchMark D5F3 Ventana + BenchMark ALK NSCLC 32 ALK NSCLC 28 FISH IHC 4 D5F3 Ventana D5F3 Cell Signaling 1A4 /1H7 5A % 84. 4% 93. 8% 56. 3% 100% D5F3 Ventana + BenchMark 96. 7% 91. 7% 96. 7% 76. 7% ALK IHC ALK NSCLC D5F3 Ventana IHC FISH R doi /j. cnki. cjcep A Comparative study of ALK antibody with manual and automatic immunohistochemical detection in non-small cell lung cancer SHEN Qin WANG Xuan YU Bo LIU Biao XU Yan WANG Yan-fen XIA Qiu-yuan ZHOU Xiao-jun Department of Pathology Nanjing General Hospital of Nanjing Military Area Command Nanjing Abstract Purpose China To explore the immunohistochemical IHC expression of ALK antibodies with different clones in anaplastic lymphoma kinase ALK gene fusion non-small cell lung cancer NSCLC. Methods ALK expression in 60 NSCLCs were detected by IHC including autostainer D5F3 Ventana + BenchMark and manual staining using 4 different antibodies of D5F3 Ventana D5F3 Cell Signaling 1A4 /1H7 OriGene 5A4 Abcam and all cases were verified with ALK FISH. Their expressions with 4 antibodies were compared with those by D5F3 Ventana + BenchMark. Results 32 ALK gene rearrangement NSCLCs and 28 negative cases were identified by FISH and D5F3 Ventana + BenchMark. The sensitivity of D5F3 Ventana D5F3 Cell Signaling 1A4 / 1H7 OriGene 5A4 Abcam was 93. 8% 84. 4% 93. 8% 56. 3% and all the speciticity was 100%. The consistency with D5F3 Ventana + BenchMark was 96. 7% 91. 7% 96. 7% and 76. 7% respectively. The validity of immunohistochemical staining in surgical resection specimens was better than in small biopsies. Conclusion high-affinity antibody clone may provide a more economic and widespread pre-screening technique. Key words lung neoplasm non-small cell lung cancer ALK immunohistochemistry screening Effective routine manual immunohistochemistry with non-small cell lung cancer anaplastie lymphoma kinase ALK NSCLC 85% 5 NSCLC ALK Crizotinib 15% 1 2 ALK qinshen2005@ 163. com fluorescent in situ hybridization FISH RT-PCR immunohistochemistry IHC 3 IHC IHC NSCLC

2 269 ALK IHC ~ 82 ALK Ⅰ + Ⅱ NSCLC 2. 2 D5F3 Ventana + BenchMark 32 D5F3 Ventana + BenchMark 28 10% FISH 4 μm HE IHC ALK 2 ALK D5F3 D5F3 Ventana Tucson AZ ALK Vision DAKO IHC IHC 4 > 75% > 50% FISH Vysis LSI ALK Abbott Molecular Abbott Park IL ALK 3 5 HE 100 ALK > 15% ALK ALK NSCLC 38 Ⅲ + Ⅳ cm 0. 9 ~ 12 cm D5F3 Ventana + BenchMark ALK 32 ALK NSCLC % 30 / % 27 / % 30 /32 18 D5F3 Cell Signaling Technology Billerica MA % 18 /32 ~ 65. 6% ALK 1A4 /1H7 OriGene USA ALK 62. 5% 68. 8% 21. 9% 4 5A4 Abcam UK 1 50 En- 100% 93. 8% 93. 3% ALK 4 IHC 60 NSCLC ALK % D5F3 Ventana D5F3 Cell Signaling 1A4/1H7 OriGene 5A4 Abcam FISH % % ~ 90% IHC 1 ALK D5F3 8 ~ D5F3 Ventana Tucson AZ Ventana 25% IHC BenchMark Ventana Tucson AZ IHC D5F3 Ventana Ventana OptiView ALK D5F3 Cell Signaling 1A4 /1H7 OriGene 5A4 Abcam En- Vision IHC 60 NSCLC EnVision IHC % D5F3 D5F3 1A4 /1H7 5A4 Ventana Cell Signaling OriGene Abcam IHC IHC D5F3 Ventana + BenchMark 4 D5F3 Ventana D5F3 Cell Signa-

3 270 ling 1A4 /1H7 OriGene 5A4 Abcam 96. 7% 91. 7% 96. 7% 76. 7% 4 IHC TFG-ALK KIF5B-ALK KLC1-30% ~ 100% ALK 40. 6% 2 ~ ALK ALK 7 NSCLC IHC 95% 95% 95% 65% % 66. 7% 91. 7% 41. 7% NSCLC ALK 9 4 ~ 75% 75% 90% 30% 30% 40% 55% 25% ALK ALK ALK 3% ~ D5F3 Ventana + BenchMark 7 3 EML4 ALK NSCLC ALK EML4-ALK ALK ALK % 10 NSCLC ALK FISH NSCLC ALK FISH 2007 Soda 6 IHC D5F3 Ventana IHC BenchMark OptiView ALK 2 1A4 /1H7 OriGene D5F3 Ventana IHC ~ EnVision 3 D5F3 Cell Signaling IHC EnVision 4 5A4 Abcam IHC + EnVision 5 D5F3 Ventana IHC Ventana D5F3 + BenchMark + OptiView 6 1A4 /1H7 OriGene D5F3 Ventana IHC EnVision 7 1A4 /1H7 OriGene D5F3 Ventana D5F3 Cell Signaling 5A4 Abcam IHC ~ EnVision

4 271 ALK NSCLC ALK 1A4 /1H7 OriGene Mino-Kenudson 11 ALK IHC IHC D5F3 IHC ALK NSCLC IHC D5F3 Ventana IHC BenchMark ALK FISH D5F3 Ventana + BenchMark OptiView DAB OptiView Houang 16 ALK IHC IHC BenchMark IHC D5F3 5 Ventana 16 10% IHC D5F3 6 ~ 12 h Ventana + BenchMark 4 8 ~ 18 h % ~ 96. 7% FISH 100% IHC IHC 17 ALK Hutarew IHC ALK 2 Ali 18 1 / EGFR /KRAS ALK ALK 5 IHC ALK Hutarew 5 D5F3 Cell Signaling ALK IHC 25 ALK 12% 48% 40% FISH % 96. 2% Conklin % 75% Cabillic 14 5A4 Abcam IHC BenchMark NSCLC 72% IHC ALK Zhou 4 15 D5F3 Cell Signaling IHC ALK 4 1A4 /1H7 3 ALK FISH D5F3 Ventana + BenchMark IHC IHC ALK NSCLC 1 Fu S Wang F Shao Q et al. Detection of EML4-ALK fusion gene in chinese non-small cell lung cancer by using a sensitive quantitative real-time reverse transcriptase PCR technique J. Diagn Mol Pathol Epub ahead of print. 2 Siegel R Naishadham D Jemal A. Cancer statistics 2012 J. CA Cancer J Clin

5 Zhou J Zhao J Sun K et al. Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening J. PLoS One e Hutarew G Hauser-Kronberger C Strasser F et al. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC evaluation of five different ALK antibody clones and ALK FISH J. Histopathology Soda M Choi Y L Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer J. Nature Shackelford R E Vora M Mayhall K et al. ALK-rearrangements and testing methods in non-small cell lung cancer a review J. Genes Cancer Gorczynski A Prelowska M Adam P et al. ALK-positive cancer still a growing entity J. Future Oncol Lindeman N I Cagle P T Beasley M B et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors guideline from the college of american pathologists international association for the study of lung cancer and association for molecular pathology J. J Mol Diagn Desai S S Shah A S Prabhash K et al. A year of anaplastic large cell kinase testing for lung carcinoma pathological and technical perspectives J. Indian J Cancer ALK 11 Mino-Kenudson M Chirieac L R Law K et al. A novel highly 2013 J. sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry J. Clin Cancer Res Selinger C I Rogers T M Russell P A et al. Testing for ALK rearrangement in lung adenocarcinoma a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization J. Mod Pathol Conklin C M Craddock K J Have C et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent J. J Thorac Oncol Cabillic F Gros A Dugay F et al. Parallel FISH and immunohistochemical studies of ALK status in non-small-cell lung cancers reveal major discordances J. J Thorac Oncol Li Y Pan Y Wang R et al. ALK-rearranged lung cancer in Chinese a comprehensive assessment of clinicopathology IHC FISH and RT-PCR J. PLoS One e Houang M Toon C W Clarkson A et al. Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer J. Pathology J. ALK FISH Ali G Proietti A Niccoli C et al. EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma a case report J. Lung Cancer CIC-FOXO4 6 SRCS CD99 WT1 ~ Sugita S Arai Y Tonooka A et al. A novel CIC-FOXO4 gene CIC fusion in undifferentiated small round cell sarcoma a genetically FOXO4 distinct variant of Ewing-like sarcoma. Am J Surg Pathol 2014 CIC-FOXO4 ESFT Ewing' s sarcoma family tumor ES- CIC-FOXO4 FT SRCS SRCS ESFT EWSR1-ETS / 1 X 19 Q13 q CIC-FOXO mm